July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
A Randomized, Multi-Center, Double-Masked, Vehicle-Controlled, Parallel-Group Phase 2b Allergic Conjunctivitis Clinical Trial of Topical Ocular ADX-102, a Novel Aldehyde Sequestering Agent
Author Affiliations & Notes
  • Paul J Gomes
    Ora, Inc., Andover, Massachusetts, United States
  • Todd Brady
    Aldeyra Therapeutics, Lexington, Massachusetts, United States
  • David Hollander
    Ora, Inc., Andover, Massachusetts, United States
  • David Clark
    Aldeyra Therapeutics, Lexington, Massachusetts, United States
  • Footnotes
    Commercial Relationships   Paul Gomes, Ora, Inc. (E); Todd Brady, Aldeyra Therapeutics (E); David Hollander, Ora, Inc. (E); David Clark, Aldeyra Therapeutics (E)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 5571. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Paul J Gomes, Todd Brady, David Hollander, David Clark; A Randomized, Multi-Center, Double-Masked, Vehicle-Controlled, Parallel-Group Phase 2b Allergic Conjunctivitis Clinical Trial of Topical Ocular ADX-102, a Novel Aldehyde Sequestering Agent. Invest. Ophthalmol. Vis. Sci. 2018;59(9):5571. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Pro-inflammatory aldehyde mediators potentiate allergic (TH2) and auto-immune (TH1) inflammation. ADX-102 is a novel aldehyde sequestering agent that represents a new anti-inflammatory drug class in development for the treatment of the immediate post-histaminic inflammatory phase of allergic conjunctivitis (AC) and other ocular inflammatory diseases. Post-histaminic AC, which begins 5 to 10 minutes following allergen exposure, is distinct from the acute histamine-mediated phase of AC that is partially prophylactically modulated by antihistamines. This Phase 2b clinical trial evaluated the safety and efficacy of 0.1% and 0.5% topical ocular ADX-102 in the Conjunctival Allergen Challenge (Ora-CAC®) model in subjects with allergic conjunctivitis.

Methods : A randomized, multi-center, double-masked, vehicle-controlled, parallel-group trial of 0.1% and 0.5% ADX-102 topical ophthalmic solution was conducted in 154 subjects with seasonal and perennial AC at 5 US sites. Subjects were randomized (1:1:1) to receive 0.1% ADX-102, 0.5% ADX-102, or vehicle drops bilaterally. Subjects were challenged ~60 minutes after dosing (1-hour duration CAC). Approximately 14 days later, subjects were dosed again and challenged ~10 minutes after dosing (10-minute onset CAC). Subject-reported ocular itching (range 0 to 4) was recorded from 5 to 60 minutes post-CAC.

Results : Subject-reported ocular itching was statistically lower in the 0.5% ADX-102 group vs. the vehicle group 10 minutes (p=0.0164), 20 minutes (p=0.0379) and 30 minutes (p=0.0347) post-challenge at the 10-minute onset of action CAC visit. In seasonal allergic conjunctivitis patients, ocular itch score area under the curve 10 to 60 minutes post-challenge was statistically lower in the ADX-102 groups than the vehicle group (0.1% ADX-102 p=0.02 and 0.5% ADX-102 p=0.004). In a responder analysis (1-point improvement from baseline on the ocular itching scale), the responder odds ratio vs. vehicle was greater than 3 (p=0.02) for each of the ADX-102 groups. Both concentrations of ADX-102 were safe and well tolerated.

Conclusions : ADX-102 treatment was effective in the treatment of itching during the immediate post-histaminic inflammatory phase of AC. The durability of activity of ADX-102 over one-hour post-challenge in the CAC model exceeds that reported for antihistamines.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×